Clinical trials: Gastro-oesophageal Reflux
Reflux Oesophagitis
Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men
The objectives of the study were: To assess the safety, tolerability and pharmacokinetics of YF476 in healthy volunteers. To select a dose or doses of YF476 for detailed pharmacodynamic studies in healthy volunteers.
- Trial name
- NCT01538784
- Testing
- YF476
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Esophagitis, Reflux, Esophagitis, Peptic
Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis
The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
- Trial name
- NCT00255164
- Testing
- Dexlansoprazole MR
- Where
- 96 sites in United States
- Volunteers
- 451 people
- Sponsor
- Takeda
Nocturnal Symptoms of GERD, Sleep Disorders in GERD
QUality of Sleep Improvement With Evening Topical Therapy for Non-Erosive Gastroesophageal Reflux Disease (The QUIET Trial)
The goal of this randomized, double-blind, single-center clinical trial is to learn if medical devices work to decrease nocturnal symptoms of GERD gastroesophageal reflux disease in adults' patients and improve sleeping time…
- Conditions
- Nocturnal Symptoms of GERD, Sleep Disorders in GERD, GERD (Gastroesophageal Reflux Disease), Non-Erosive Gastro-Esophageal Reflux Disease
- Trial name
- QUIET (NCT07700342)
- Where
- 2 sites in Poland
- Volunteers
- 50 people
- Sponsor
- Cellmedis
Esophagitis, Reflux, Esophagitis, Peptic
Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis
The purpose of this study is to assess the ability of once-daily (QD) treatment with dexlansoprazole modified release (MR) 30 mg and 60 mg or placebo in maintaining healing of erosive esophagitis (EE).
- Trial name
- NCT00321737
- Testing
- Dexlansoprazole MR
- Where
- 98 sites in United States, Australia and 6 more
- Volunteers
- 445 people
- Sponsor
- Takeda
Gastro-oesophageal Reflux Disease
Evaluation of GERDOFF Efficacy in Combination With Proton Pump Inhibitor
The aim of the present study was to evaluate the effect of a 6-weeks treatment of a CE-marked combination oral formulation of hyaluronic acid with chondroitin sulphate and aluminium hydroxide (GERDOFF®), in addition to proton…
- Trial name
- NCT03793556
- Testing
- GERDOFF® + Omeprazole, Omeprazole
- Where
- Italy
- Volunteers
- 72 people
- Sponsor
- SOFAR S.p.A.
Acid Reflux, Gastro Oesophageal Reflux Disease
A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions
The purpose of this study is to assess the effectiveness of Zegerid 20mg capsules and powder and Losec 20mg capsules in healthy volunteers under fasting conditions.
- Trial name
- NCT01710995
- Testing
- Zegerid, Losec
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Norgine
Ulcerative Colitis, Crohn Disease
Systems Biology of Gastrointestinal and Related Diseases
This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and…
- Conditions
- Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp
- Trial name
- NCT05579444
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Viome
Barrett Esophagus, Gastro Esophageal Reflux
Clinical Utility of WATS3D: A 5-Year Prospective Study
The purpose of this study is to create a registry (collect data and keep it in a research database) to learn more about two methods of taking small tissue samples from your esophagus (the esophagus is the tube that carries food…
- Conditions
- Barrett Esophagus, Gastro Esophageal Reflux, Esophageal Dysplasia, Esophageal Diseases
- Trial name
- NCT04312633
- Where
- United States
- Volunteers
- 90,000 people
- Sponsor
- CDx Diagnostics
Gastroesophageal Reflux, Heartburn
A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)
The purpose of the study is to confirm the safety and effectiveness of rabeprazole in the treatment of patients with erosive or ulcerative gastroesophageal reflux disease (GERD) in routine primary health care.
- Trial name
- NCT00216489
- Testing
- rabeprazole sodium
- Volunteers
- 191 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
Gastric Ulcer (GU), Duodenal Ulcer (DU)
A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in Japanese paediatric patients aged 1 to 14 years old…
- Conditions
- Gastric Ulcer (GU), Duodenal Ulcer (DU), Anastomotic Ulcer (AU), Non-erosive Reflux Esophagitis Disease (NERD)
- Trial name
- NCT02153398
- Testing
- D961H sachet 10 mg, D961H capsule 10mg, D961H capsule 20 mg
- Where
- 15 sites in Japan
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Esophagitis, Gastroesophageal Reflux
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
S-Tenatoprazole-Na (STU-Na), a new drug currently under clinical development, belongs to a class of drugs, called proton pump inhibitors (PPls). Some PPIs are already commercially available.
- Conditions
- Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
- Trial name
- NCT00284908
- Testing
- S-Tenatoprazole-Na (STU-Na)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- STEBA France
Regurgitation, Gastric, Diarrhea
To Assess the Safety and Tolerance of Infant Formula With Locust Bean Gum in Infants With Regurgitation
A randomized, controlled study to evaluate the safety and tolerance of an infant formula with locust bean gum in infants with regurgitation. (Solar)
- Trial name
- Solar (NCT04042454)
- Testing
- milk based anti-regurgitation infant formula, Milk based infant formula
- Where
- 16 sites in Italy, Poland and 1 more
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Nutricia Research
Diabetes Mellitus
Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion
The present study will compare lixisenatide and liraglutide in a population of subjects with T2DM not optimally controlled on OADs and / or insulin, which is the target population for these medications.
- Trial name
- NCT02231658
- Testing
- Liraglutide, Lixisenatide
- Where
- 2 sites in Germany
- Volunteers
- 109 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Reflux Esophagitis
The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD
The purpose of this study is to assess the efficacy and safety of Newrabell® Tab. in patients with refractory reflux esophagitis to the prior standard PPIs regimen.
- Trial name
- NCT01860482
- Testing
- Newrabell® Tablet 10mg
- Where
- 2 sites in South Korea
- Volunteers
- 39 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Peptic Ulcer, Gastroesophageal Reflux
S-CEI of Nexium in Paediatric Patients
To capture safety and efficacy when Nexium are administered to pediatric patients in clinical practice after launch
- Trial name
- NCT03562026
- Where
- 31 sites in Japan
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Erosive Esophagitis
A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically…
- Trial name
- NCT05055128
- Testing
- X842, X842 Dummy, Lansoprazole
- Where
- 42 sites in United States, Bulgaria and 6 more
- Volunteers
- 248 people
- Sponsor
- Cinclus Pharma Holding AB
Gastroesophageal Reflux
Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)
The purpose of this study is to determine the effect of vonoprazan compared to esomeprazole for preventing heartburn symptoms over a 4-week treatment period in participants who have a partial response to treatment with…
- Trial name
- NCT02743949
- Testing
- Vonoprazan, Esomeprazole
- Where
- 39 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 256 people
- Sponsor
- Takeda
Reflux Esophagitis, Gastroesophageal Reflux
A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis
A phase 2, randomized, double-blind, double-dummy, positive drug parallel controlled, multicenter trial to evaluate efficacy and safety of within 8 weeks (including 8 weeks) treatment of Anaprazole 40mg QD, 60mg QD compared with…
- Conditions
- Reflux Esophagitis, Gastroesophageal Reflux, Esophagitis, Esophageal Motility Disorders
- Trial name
- NCT05604261
- Testing
- Anaprazole sodium 40 mg, Anaprazole sodium 60 mg, Rabeprazole sodium 20 mg
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Gastroesophageal Reflux
Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -
The purpose of the study is to verify superiority of the lafutidine group over the placebo group and non-inferiority to the famotidine group in terms of endoscopic healing rate of the patients with mild reflux oesophagitis.
- Trial name
- NCT00229424
- Testing
- Lafutidine, Famotidine
- Where
- Japan
- Volunteers
- 325 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Reflux Esophagitis (RE)
A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis
To evaluate the efficacy and safety of JP-1366 tablets and Nexium® (Esomeprazole magnesium enteric-coated tablets) in subjects with reflux esophagitis.
- Trial name
- NCT06850480
- Testing
- JP-1366 simulation tablets, Esomeprazole Magnesium (Nexium) simulation tablets
- Where
- China
- Volunteers
- 356 people
- Sponsor
- Livzon Pharmaceutical Group Inc.